Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapagliflozin versus acarbose in newly diagnosed type 2 diabetes mellitus
ChiCTR1900023470Phase 4Not yet recruiting
- Sponsor
- Zhu Xianyi Memorial Hospital
- Start
- Jun 2019
- Modality
- Small Molecules, Microbiome-Derived Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of dapagliflozin and acarbose in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Zhu Xianyi Memorial Hospital. Primary endpoints: Renal cortical perfusion level, Kidney tissue oxygenation status and 3 more. Planned start Jun 2019; status: not yet recruiting.
02
Drugs
dapagliflozinacarbose
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on ChiCTR1900023470.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900023470.